ArriVent BioPharma, Inc. (AVBP)
NASDAQ · Manufacturing · Pharmaceutical preparations
$28.45−$1.65 (−5.48%) on the dayAs of the close; data may be delayed.
AVBP price, last 12 months
Key stats
- Previous close
- $30.10
- Open
- $30.16
- Day range
- $28.43 – $30.55
- 52-week range
- $17.00 – $35.83
- Volume
- 653.2K
- Avg volume (20 days)
- 579.7K
- Market cap
- $1.4B
Performance
1W−1.6%
1M−8.6%
3M−16.3%
6M+30.5%
YTD+41.4%
1Y+59.3%
vs S&P 500, 1Y+42.5 pts
Technicals and fundamentals
About ArriVent BioPharma, Inc.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.4B